tbuckley/cabot-search huggingface dataset:
A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients
Authors: E. H. Rubin, G. I. Shapiro, M. N. Stein, P. Watson, D. Bergstrom, A. Xiao, J. B. Clark, S. J. Freedman, J. P. Eder
Journal: Journal of Clinical Oncology (2006)

3009 Background: The AKs are essential for mitotic progression, spindle formation, centrosome maturation, chromosomal segregation, and cytokinesis. Elevated expression occurs frequently in tumors. MK-0457 (VX-680) is a potent AK inhibitor, with Ki values of 0.66, 18 and 4.6 nM for AKs A, B and C, respectively. MK-0457 inhibits proliferation of transformed cells in vitro (IC 50 ’s 15–113 nM), and induces colon and pancreatic cancer xenograft regressions. Methods: After IRB approval, consenting patients (pts) with refractory solid tumors (median 3 prior regimens, range 2–6) and adequate hematologic and organ function were enrolled using an accelerated dose escalation scheme with 1–2 pts/dose level until ≥ grade 2 toxicity, followed by 3–6 pts/level. MK-0457 was administered by continuous 5-day intravenous infusion every 28 days. Dose-limiting toxicity (DLT) was grade 3 non-hematologic or grade 4 hematologic toxicity ≥ 5 days, or grade 4 febrile neutropenia (FN) during cycle 1. PKs were collected pre-dose through 168 h and analyzed for MK-0457 and metabolites by HPLC/mass spec. Steady state volume of distribution (Vd ss ), clearance (CL), maximal concentration (Cmax) and terminal half-life (t 1/2 ) were determined by WinNonLin. Results: 16 pts received MK-0457 dosed at 0.5, 1, 2, 4, 8, and 12 mg/m 2 /h. Median number of cycles was 2 (range 1–6). DLT was asymptomatic neutropenia ≥ 5 days at 12 mg/m 2 /h. At 8 mg/m 2 /h, 1 pt experienced FN in cycle 2; a second developed a grade 2 allergic reaction. Three pts achieved stable disease as best response, and two of them completed 6 cycles. Plasma concentrations reached steady state rapidly (i.e., within 24 h) and declined biexponentially after the end of infusion; after a rapid initial decay, a slower decaying terminal phase demonstrated a t 1/2 ∼15 h. PK parameters include Vd ss = 237 ± 107 (SD) L/m 2 and CL = 517 ± 141 ml/min/m 2 . At 8 mg/m 2 /h, Cmax was ∼650 nM. Conclusion: MK-0457 is generally well tolerated and achieves plasma levels similar to those causing regressions in xenografts. CL is high and exposures achieved are roughly dose proportional. Because 8 mg/m 2 /h was well tolerated in heavily pre-treated pts, escalation to 10 mg/m 2 /h is underway. Baseline tumor samples will be assessed for predictive biomarkers at the recommended phase II dose. [Table: see text]
ENDOTHELIAL DYSFUNCTION POST TRANSRADIAL ACCESS CORONARY CATHETERIZATION: A CLINICAL STUDY AND META-ANALYSIS OF PUBLISHED LITERATURE
Authors: Alexis S. Antonopoulos, George Latsios, Evangelos Oikonomou, Georgia Vogiatzi, Angelos Papanikolaou, Gerasimos Siasos, Eleftherios Tsiamis, Konstantinos Toutouzas, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2017)
How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition
Authors: Stephanie J W Shoop-Worrall, Suzanne M M Verstappen, Eileen Baildam, Alice Chieng, Joyce Davidson, Helen Foster, Yiannis Ioannou, Flora McErlane, Lucy R Wedderburn, Wendy Thomson, Kimme L Hyrich
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> Many criteria for clinically inactive disease (CID) and minimal disease activity (MDA) have been proposed for juvenile idiopathic arthritis (JIA). It is not known to what degree each of these criteria overlap within a single patient cohort. This study aimed to compare the frequency of MDA and CID across different criteria in a cohort of children with JIA at 1 year following presentation. <h3>Methods</h3> The Childhood Arthritis Prospective Study recruits children at initial presentation to paediatric or adolescent rheumatology in seven UK centres. Children recruited between October 2001 and December 2013 were included. The proportions of children with CID and MDA at 1 year were calculated using four investigator-defined and eight published composite criteria. Missing data were accounted for using multiple imputation under different assumptions. <h3>Results</h3> In a cohort of 1415 children and adolescents, 67% patients had no active joints at 1 year. Between 48% and 61% achieved MDA and between 25% and 38% achieved CID using published criteria. Overlap between criteria varied. Of 922 patients in MDA by either the original composite criteria, Juvenile Arthritis Disease Activity Score (JADAS) or clinical JADAS cut-offs, 68% were classified as in MDA by all 3 criteria. Similarly, 44% of 633 children with CID defined by either Wallace9s preliminary criteria or the JADAS cut-off were in CID according to both criteria. <h3>Conclusions</h3> In a large JIA prospective inception cohort, a majority of patients have evidence of persistent disease activity after 1 year. Published criteria to capture MDA and CID do not always identify the same groups of patients. This has significant implications when defining and applying treat-to-target strategies.
SUDDEN AND FATAL MALFUNCTION AFTER CONTINUOUS-FLOW LEFT VENTRICULAR ASSIST DEVICES: AN URGENT CALL FOR REGULAR INSPECTIONS
Authors: Rahat Muslem, Sakir Akin, Alina Constantinescu, Olivier Manintveld, Ozcan Birim, Ad J.J.C. Bogers, Kadir Caliskan
Journal: Journal of the American College of Cardiology (2017)
A multicentre, prospective phase 2 study of weekly schedule of carboplatin (C) plus paclitaxel (P) in first-line treatment of elderly patients (pts) with ovarian cancer (OC). The MITO (Multicentre Italian Trials in Ovarian cancer)-5 study
Authors: V. Zagonel, G. Ferrandina, R. De Vivo, A. De Matteis, A. Fabbrocini, D. Natale, G. Cavazzini, P. Scollo, M. Di Maio, S. Pignata
Journal: Journal of Clinical Oncology (2006)

15012 Background: CP every 3 weeks is the standard for pts with OC, but elderly pts frequently receive modified schedules or single agent chemotherapy to avoid toxicity. A prospective phase 2 study was conducted to describe tolerability and activity of a weekly schedule of CP in elderly pts with OC. Methods: Pts aged ≥70 years with chemo-naive OC, stage IC-IV, ECOG PS≤2 were eligible. Treatment was C (AUC 2) + P (60 mg/m 2 ) on days 1, 8, 15 every 4 weeks, up to 6 cycles. A 2-stage minimax design was applied. With rate of pts without unacceptable toxicity in the first 3 cycles (UT) as primary endpoint, alpha 0.05 and beta 0.10, p 0 =0.75, p 1 =0.95, ≥23/26 pts without UT were required at the final stage. Toxicity was coded with NCI-CTC and response by RECIST. Geriatric assessment was performed by ADL (Activities of Daily Living) and IADL (Instrumental ADL). Results: 26 pts were enrolled. Median age was 77 (range 70–84). PS0: 10 pts, PS1: 16 pts. 14 pts (53.8%) had ≥2 comorbidities. 32%/72% had some ADL/ IADL dependency, respectively. 23 pts (88.5%) did not suffer UT. The 3 UT recorded were g3 heart rhythm (1 pt), g3 liver (1 pt), prolonged haematological toxicity (1 pt). Other main toxicities: g3 thrombocytopenia 1 pt, g2 constipation 2 pts (8%), g1 neuropathy 4 pts (15%). Out of 13 pts with at least one measurable lesion, 4 partial responses were observed (response rate 30.8%, 95% exact CI: 9.1–61.4). Out of 6 pts with non-measurable disease and 2 pts evaluable only for Ca125, 4 complete responses were observed (50%). Conclusions: In this series of elderly OC pts, characterized by a high incidence of comorbidities and functional impairment, weekly CP has a favourable toxicity profile. In this setting, a comparison of weekly vs 3-weekly CP is advisable to compare efficacy. No significant financial relationships to disclose.
TRENDS IN DISCHARGE AND OUTCOME OF DUAL ANTIPLATELET THERAPY POST PERCUTANEOUS INTERVENTION IN HIGH BLEEDING RISK POPULATION
Authors: Ron Waksman, M. Chadi Alraies, Kyle Buchanan, Edward Koifman, Arie Steinvil, Toby Rogers, Jiaxiang Gai, Rebecca Torguson, Itsik Ben-Dor, Augusto Pichard, Lowell Satler
Journal: Journal of the American College of Cardiology (2017)
TECHNIQUE AND UTILITY OF CT ANGIOGRAPHY FLUOROSCOPY IMAGE FUSION TO GUIDE PERCUTANEOUS PULMONARY VALVE IMPLANTATION IN ADULTS
Authors: Akanksha Thakkar, Ponraj Chinnadurai, Basel Ramlawi, John Breinholt, Gary Monteiro, Alan Lumsden, C. Huie Lin
Journal: Journal of the American College of Cardiology (2017)
Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer
Authors: Fan Mo, Dong Lin, Mandeep Takhar, Varune Rohan Ramnarine, Xin Dong, Robert H. Bell, Stanislav V. Volik, Kendric Wang, Hui Xue, Yuwei Wang, Anne Haegert, Shawn Anderson, Sonal Brahmbhatt, Nicholas Erho, Xinya Wang, Peter W. Gout, James Morris, R. Jeffrey Karnes, Robert B. Den, Eric A. Klein, Edward M. Schaeffer, Ashley Ross, Shancheng Ren, S. Cenk Sahinalp, Yingrui Li, Xun Xu, Jun Wang, Jian Wang, Martin E. Gleave, Elai Davicioni, Yinghao Sun, Yuzhuo Wang, Colin C. Collins
Journal: European Urology (2017)
Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): Subgroup analysis of TURANDOT.
Authors: Moshe J. Inbar, Istvan Lang, Zsuzsanna Kahan, Richard Greil, Semir Beslija, Salomon M. Stemmer, Bella Kaufman, Silke Ahlers, Thomas Brodowicz, Christoph Zielinski
Journal: Journal of Clinical Oncology (2013)

1040 Background: The randomized phase III TURANDOT trial compared first-line BEV plus paclitaxel (PAC) vs BEV plus capecitabine (CAP) in HER2-negative metastatic BC (mBC). BEV-based regimens are often favored in TNBC [Dawood 2012] because of efficacy in subgroup analyses and a lack of effective treatments. We performed an exploratory subgroup analysis of TURANDOT to provide more data on BEV-based therapy in TNBC. Methods: Patients (pts) with HER2-negative mBC who had received no prior chemotherapy for mBC were randomized to either BEV–PAC (BEV 10 mg/kg d1 and 15 + PAC 90 mg/m 2 d1, 8, and 15 q4w) or BEV–CAP (BEV 15 mg/kg d1 + CAP 1000 mg/m 2 bid d1–14 q3w). The primary endpoint was overall survival (OS); secondary endpoints included objective response rate (ORR), progression-free survival (PFS), and safety. Results: Of 561 pts treated, 130 had TNBC. Baseline characteristics were typical of a poor-prognosis population and generally balanced between treatment arms, although fewer pts receiving BEV–PAC than BEV–CAP had ECOG PS 1/2 (25% vs 40%, respectively), positive lymph nodes (56% vs 72%), metastatic disease at first diagnosis (19% vs 30%), and liver metastases (27% vs 43%). Median age was 54 vs 56 years, respectively. At data cut-off, median follow-up was 21.4 vs 19.2 mo for BEV–PAC and BEV–CAP, respectively. The safety profiles in the TNBC subgroup were similar to the overall population. The predominant grade ≥3 AEs were hematologic AEs and neuropathy with BEV–PAC and hand-foot syndrome and diarrhea with BEV–CAP. Conclusions: One-year OS rates up to 78% in TURANDOT are among the highest seen in TNBC. BEV-based therapy is a valid option in a setting with limited active treatments. BEV–PAC may be favored based on 1-year OS, PFS, and ORR. Clinical trial information: NCT00600340. [Table: see text]
Clinical Monoclonal B Cell Lymphocytosis Is a Strong Favorable Prognosticator Independent From Biological and Clinical Parameters,
Authors: Giovanni Del Poeta, Maria Ilaria Del Principe, Francesco Buccisano, Annalisa Biagi, Pietro Bulian, Fabrizio Luciano, Antonella Zucchetto, Luca Maurillo, Pasquale Niscola, Alessio Pio Perrotti, Adriano Venditti, Valter Gattei, Paolo de Fabritiis, Sergio Amadori
Journal: Blood (2011)
Severe Thrombocytopenia (&lt;50×109 Cells/l) Associated with Glycoprotein IIb/IIIa Inhibitors in Patients with Cardio Vascular Illness: A Cohort Study On Clinical Course and Outcomes.
Authors: Girish N Viswanathan, Gnanamoorthy Mayurathan, John Hardy, Sheila Jamieson, Patrick Kestevan, Azfar Zaman
Journal: Blood (2009)
Stool DNA Testing to Screen for Colorectal Cancer in the Medicare Population
Authors: Iris Lansdorp-Vogelaar, Karen M. Kuntz, Amy B. Knudsen, Janneke A. Wilschut, Ann G. Zauber, Marjolein van Ballegooijen
Journal: Annals of Internal Medicine (2010)

Stool DNA testing is less accurate and more expensive than other colorectal cancer screening tests. Regardless, the Centers for Medicare & Medicaid Services has considered whether to reimburse it f...
Interleukin‐32 is highly expressed in lesions of hidradenitis suppurativa
Authors: R. Thomi, D. Yerly, N. Yawalkar, D. Simon, C. Schlapbach, R.E. Hunger
Journal: British Journal of Dermatology (2017)

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Its immunopathogenic mechanisms are still poorly understood. Previous studies demonstrated that the proinflammatory cytokine interleukin (IL)-32 is implicated in the pathogenesis of other inflammatory diseases.To investigate the tissue expression and systemic levels of IL-32, as well as its cellular sources, in patients with HS in comparison with healthy donors and patients with two other inflammatory skin diseases: psoriasis and atopic dermatitis (AD).Tissue samples were obtained from healthy skin and lesional HS, psoriatic and AD skin to analyse the expression of IL-32 by immunohistochemistry and semiquantitative real-time polymerase chain reaction. The cellular source of the cytokine was determined by double immunofluorescence staining. Serum from the four donor groups was used to measure systemic levels of IL-32 by enzyme-linked immunosorbent assay.IL-32 was upregulated in patients with HS in both lesional skin and serum when compared with healthy donors and patients with AD or psoriasis. In HS, IL-32 was found to be expressed by natural killer cells, T cells, macrophages and dendritic cells in highly infiltrated areas of the dermis. High IL32 mRNA levels in lesional HS skin coincided with high amounts of T cells and macrophages. Additionally, IL32 mRNA levels in lesional HS skin correlate positively with interferon-γ and IL-17A and negatively with IL-13.Our findings suggest that IL-32 is overexpressed in HS. Targeting IL-32 may therefore represent a new therapeutic option for the treatment of this recalcitrant disease.
Breast cancer (BC) risk among 3-year survivors of a first pediatric cancer (FC)
Authors: C. Guibout, E. Adjadj, A. Shamsaldin, O. Oberlin, F. De Vathaire
Journal: Journal of Clinical Oncology (2004)

8531 Background: Long-term survival of patients treated for a pediatric cancer is dramatically improved. Nevertheless, in this context, the risk for occurrence of subsequent cancer, and particularly of breast cancer knowing that child's breast is very radiosensitive, is a significant data for the monitoring of the survivors. Methods: Data on chemotherapy and radiotherapy were collected for each of the 1,817 3-year female, survivors from a FC diagnosed before age 17, treated in eight French and English centers. Individual estimation of radiation dose to each breast was performed for the 1,261 patients treated by external radiotherapy, delivered in 24 fractions (mean); mean dose to breasts was 5.06 Gy (range 0.0–78.6). Results: Within a 16-year mean follow-up, sixteen BC occurred leading to a cumulative probability of 2.9% [95%CI: 0.98–4.9] 30 years after the FC and of 5.5% [95%CI: 2.1 to 8.9 %] at age 40. The annual excess incidence rose as age increased whereas the Standardized Incidence Ratio (SIR) decreased. On average, each Gy received to the breast increases the risk by 0.78 [95%CI: 0.0–5.4]. A non significant higher risk with less than 20 fractions versus 20 or more was observed. After adjustment on radiation dose and FC type, only a weak association between chemotherapy and BC risk was evidenced (RR=2.4, 95%IC: 0.8–7.1). Adjusting on age at FC, radiation dose and chemotherapy, a higher risk of a subsequent BC was associated with Hodgkin's disease (RR=4.7, 95%CI: 1.0–19.6) and non significantly with neuroblastoma (RR =3.20, 95%CI: 0.6–12.1). Conclusions: In this study, the higher risk of occurrence of BC following childhood Hodgkin's disease seems to be due not only to a higher radiation dose to the breasts but also to a specific susceptibility. No significant financial relationships to disclose.
SOTALOL VERSUS OTHER ANTI-ARRHYTHMIC MEDICATIONS FOR CARDIOVERSION OF ATRIAL FIBRILLATION AND MAINTENANCE OF SINUS RHYTHM: META-ANALYSIS OF RANDOMIZED CONTROLLED STUDIES
Authors: Arun Kanmanthareddy, Madhu Reddy, Venkata Alla, Dixitha Anugula, Vivek Yarlagadda, Pradyumna Agasthi, Madhav Lavu, Sudharani Bommana, Donita Atkins, Claire Hunter, Aryan Mooss, Andrea Natale, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2017)
TREATMENT AND OUTCOMES OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION ACCORDING TO GUIDELINE-DEFINED ANTICOAGULATION THRESHOLDS: RESULTS FROM THE GARFIELD-AF REGISTRY
Authors: A. John Camm, Gabriele Accetta, Giancarlo Agnelli, Jean-Pierre Bassand, Samuel Goldhaber, Gloria Kayani, Frank Misselwitz, Seil Oh, Pekka Raatikainen, Alexander Turpie, Martin van Eickels, Ajay Kakkar
Journal: Journal of the American College of Cardiology (2017)
Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,
Authors: Roberto Latagliata, Massimo Breccia, Ida Carmosino, Federico Vozella, Paola Volpicelli, Antonietta Ferretti, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, Rosa De Cuia, Daniela Diverio, Mauro Nanni, Marco Mancini, Giuliana Alimena
Journal: Blood (2011)
VENOUS THROMBOEMBOLISM PROPHYLAXIS: NEED OF CONTINUOUS ASSESSMENT DUE TO CHANGES IN RISK DURING THE SAME HOSPITALIZATION
Authors: Rahul Chaudhary, Bhavina Batukbhai, Martin Sanchez, Malini Chandra Serharan, Eric Feng, Charles R. Albrecht, Mauro Moscucci
Journal: Journal of the American College of Cardiology (2017)
Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).
Authors: Andrew B. Nixon, Susan Halabi, Ivo Shterev, Mark Starr, John C Brady, Janice P. Dutcher, Judith O. Hopkins, Herbert Hurwitz, Eric Jay Small, Brian I. Rini, Phillip G. Febbo, Daniel J. George
Journal: Journal of Clinical Oncology (2013)

4520 Background: CALGB 90206 was a phase III trial of 732 pts with RCC comparing B+I versus I alone demonstrating no difference in OS. To date, there are no validated predictive biomarkers for B in RCC. For this reason, baseline plasma samples from CALGB 90206 pts were analyzed to identify and test predictive markers for B+I in RCC pts. Methods: Baseline EDTA plasma samples from 424 consenting pts were analyzed using an optimized multiplex ELISA platform for 32 candidate factors related to tumor growth, angiogenesis, and inflammation. The data were randomly split into training (n=286) and validation (n=138) sets. The proportional hazards model was used to test for treatment-marker interactions of OS. The estimated coefficients from the training set were used to compute a risk score (RS) for each pt in the validation set. The RS classified pts by risk in the validation set. The model was assessed for its predictive accuracy using area under the curve (AUC). Results: A statistically significant 3-way interaction between interleukin-6 (IL-6), hepatocyte growth factor (HGF) and treatment was observed in the training set (p&lt;0.0001). The median levels of IL-6 and HGF in the training set were 8.4 pg/ml and 89 pg/ml, respectively. In the validation set, the RS was predictive of OS (p&lt;0.001) with the high and low risk groups having a median OS of 10 months and 32 months, respectively. The AUC in the validation set was 0.82 (95% CI=0.77-0.88). The median OS (in months) by median levels of IL-6 and HGF stratified by treatment arm in the validation set is presented in the table with associated 95% CI (NR=not reached). Conclusions: IL-6 and HGF are predictive for OS in RCC patients treated with B+I and a RS based on these factors identified patients who benefitted most from B. If independently validated, this novel RS could guide clinical decisions and pt selection in future RCC trials. [Table: see text]
OPTICAL COHERENCE TOMOGRAPHY ASSESSMENT OF CORONARY ATHERECTOMY EFFECT: COMPARISON BETWEEN ORBITAL AND ROTATIONAL ATHERECTOMY IN SEVERELY CALCIFIED LESIONS
Authors: Myong Hwa Yamamoto, Akiko Maehara, Gary Mintz, Keyvan Karimigalougah, Sung Sik Kim, Kisaki Amemiya, Monica Losquadro, Elizabeth Haag, Jeffrey Moses, Fernando Sosa, Richard Shlofmitz, Masahiko Ochiai, Ziad Ali
Journal: Journal of the American College of Cardiology (2017)
THE ROLE OF BASELINE VERSUS LONG-TERM FOLLOW-UP EJECTION FRACTION IN PREDICTING ADVERSE EVENTS AMONG PRIMARY PREVENTION IMPLANTABLE CARDIOVERTER DEFIBRILLATOR RECIPIENTS
Authors: Daniel J. Friedman, Robert Overton, Linda Shaw, Marat Fudim, Divyang Patel, Eric Velazquez, Sana Al-Khatib
Journal: Journal of the American College of Cardiology (2017)
Pharmacokinetic analysis of tamoxifen metabolites in premenopausal women with early breast cancer: A substudy of NCIC CTG MA.12 randomized clinical trial.
Authors: Shahbal Bill Kangarloo, Ella S.M. Ng, Vivien H.C. Bramwell, Kathleen I. Pritchard, Lois E. Shepherd, Dongsheng Tu, Anthony M. Magliocco, Patricia A. Tang
Journal: Journal of Clinical Oncology (2014)

1524 Background: The clinical impact of CYP2D6 genetic polymorphisms on tamoxifen (Tam) remains unclear. Active metabolite levels of Tam can be influenced by drug interaction and compliance. This study evaluated the association of steady state plasma levels of Tam and its metabolites with clinical outcomes in samples collected in MA.12. Premenopausal women (n=672) with high risk node negative and node positive breast cancer following adjuvant chemotherapy were randomized to Tam or placebo. There was an improvement in DFS (HR 0.77; p=0.056) but not OS (HR 0.78; p=0.12) favoring Tam. Methods: TAM, N-desmethyl-tamoxifen (NDM), 4-hydroxy-tamoxifen (4-OH), and endoxifen (Endo) were quantified in serum by liquid chromatography–tandem mass spectrometry. Samples collected after 120 days on Tam were analyzed, (n=121 Tam, n=121 Placebo). Exploratory analyses assessed the association of DFS and OS with each metabolite level, as a continuous variable, as well as a categorical variable using an optimal cut point. Cut points were determined using the minimum p-value. Factors associated with DFS or OS were evaluated in a multivariate Cox model adjusting for age, performance status, chemotherapy, receptor status, nodal status, histology and tumor stage. Results: Baseline characteristics of the substudy were similar to the full trial population. Descriptive metabolite levels in the Tam cohort are listed in the Table. There was no crossover at 120 days. As a continuous measure, none of the metabolite values were significantly correlated with DFS or OS. As a categorical variable, only 4-OH was associated with clinical outcomes. In a multivariate Cox model, the optimal 4-OH cutpoint (1.72 ng/mL) was significantly correlated with 5 year DFS HR 0.30 [95% CI(0.10-0.95), p=0.04)] and 5 year OS HR 0.21 [95% CI(0.05-0.93), p=0.04]. Conclusions: In this exploratory, hypothesis generating analysis of MA.12, wide ranges in serum concentrations of Tam metabolites were observed. Only 4-OH levels were associated with clinical outcomes. Metabolite Mean serum [ng/mL], (range) % Coefficient of variance NDM 126.6, (0.61-293.1) 50.2 % 4-OH 1.47, (0-4.26) 56.9 % Endo 16.6, (0-52.7) 65.9 %
RACIAL (BLACK-WHITE) DISPARITIES IN THE CONTRIBUTION OF THE LONG-TERM BURDEN OF CHOLESTEROL FROM CHILDHOOD ON ADULT ANKLE-BRACHIAL INDEX DECLINE: THE BOGALUSA HEART STUDY
Authors: Camilo Fernandez-Alonso, Liqiang Zheng, Yajun Guo, Rupert Barshop, Emily Harville, Wei Chen, Lydia Bazzano
Journal: Journal of the American College of Cardiology (2017)
CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF UNFRACTIONATED HEPARIN – INSIGHTS FROM CHAMPION PHOENIX
Authors: Muthiah Vaduganathan, Robert Harrington, Gregg Stone, Philippe Steg, C. Michael Gibson, Christian Hamm, Matthew Price, Efthymios Deliargyris, Jayne Prats, Kenneth Mahaffey, Harvey White, Deepak Bhatt
Journal: Journal of the American College of Cardiology (2017)